Want to see MRNA full AI Analyst Report?
MRNA Stock Chart & Stats
$158.83
-$2.95(-5.17%)
At close: 4:00 PM EDT
$158.83
-$2.95(-5.17%)
Day’s Range― - ―
52-Week Range$22.28 - $176.66
Previous CloseN/A
Volume4.43M
Average Volume (3M)24.08M
Market Cap
$58.11B
Enterprise Value$24.02K
Total Cash (Recent Filing)$5.14B
Total Debt (Recent Filing)$1.29B
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Oct 29, 2026EPS Estimate
-1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.98
Shares Outstanding399,235,900
10 Day Avg. Volume24,249,592
30 Day Avg. Volume24,084,327
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$96.60Price Target Upside-39.18% Downside
Rating ConsensusHold
Number of Analyst Covering18
EPS Forecast (FY)-8.33
Revenue Forecast (FY)$2.10B
Bulls Say, Bears Say
Bulls Say
Respiratory Portfolio ExpansionRegulatory approvals across multiple markets and European procurement support broader commercialization of Moderna’s respiratory portfolio. This creates potential revenue diversification beyond COVID-19 and establishes distribution reach that can remain valuable through upcoming seasonal vaccine cycles.
MNEXSPIKE Market AdoptionMeaningful retail share, particularly among older adults, indicates that Moderna retains commercial traction in a competitive vaccine market. Reported real-world effectiveness also supports product differentiation and could help preserve demand as customers prioritize protection against severe disease.
Manageable LeverageLow-to-moderate leverage gives Moderna a financial cushion while it funds pipeline development and works through losses. Although shareholder equity has declined, manageable debt reduces balance-sheet pressure and preserves options for investment, restructuring, or other capital-allocation needs.
Bears Say
Deeply Negative ProfitabilityPersistent losses show that Moderna’s current cost base is not aligned with its post-pandemic revenue run rate. Negative gross profit and operating earnings weaken earnings durability, increase reliance on cash reserves, and make a sustainable return to self-funded growth dependent on successful launches and cost reductions.
Ongoing Cash BurnContinued operating and free-cash-flow outflows limit Moderna’s ability to fund development internally and steadily reduce financial flexibility. Even with substantial cash reserves, persistent burn raises the importance of execution on respiratory products, pipeline milestones, and expense discipline over the next several quarters.
Convertible Note Dilution RiskThe financing adds substantial capital but creates a lasting potential dilution burden for existing shareholders if conversion occurs. Capped calls may limit dilution within specified conditions, yet the added obligation and possible share issuance could reduce ownership participation in future company growth.
Moderna News
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $22.28 and its highest was $176.66 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $58.11B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Oct 29, 2026 which is in 52 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Jul 31, 2026. The company reported -$1.97 earnings per share for the quarter, beating the consensus estimate of -$2.032 by $0.062.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -1.1.
How many shares outstanding does Moderna have?
Moderna has 399,235,900 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$1.97 in its last earnings report, beating expectations of -$2.032. Following the earnings report the stock price went down -5.352%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$96.60 (-39.18% Downside)
$96.60 (-39.18% Downside)
Blogger Sentiment
Neutral
MRNA Sentiment 57%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 50.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 39.1%
Last 30 Days ▲ 39.1%
News Sentiment
Neutral
Bullish news 56%
Bearish news 44%
Bearish news 44%
Technicals
SMA
Positive
20 days / 200 days
Momentum
499.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.73%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Moderna
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
MRNA Company Deck
MRNA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful commercial and clinical progress — a Q2 revenue beat, multiple regulatory and market milestones (including a VRBPAC recommendation for the flu candidate and expanded approvals for respiratory products), clear cost and efficiency improvements, and advancing oncology/rare disease programs with important data and new dosing initiatives. These positives were tempered by a norovirus Phase III interim that did not meet early success criteria and slower case accrual, a significant litigation settlement payment (~$950M) that reduced cash, a substantial net loss and continued cash burn, and timing uncertainty for several event‑driven readouts. On balance, the highlights (regulatory momentum, product approvals/market uptake, cost discipline and pipeline advances) modestly outweigh the lowlights, supporting a constructive but cautious outlook.View all MRNA earnings summariesMRNA Revenue Breakdown
61.68% U.S.
2.73% Europe
35.60% Rest of World
MRNA Stock 12 Month Forecast
Average Price Target
$96.60
▼(-39.18% Downside)
Technical Analysis
Ionis Pharmaceuticals
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
―
Ownership Overview
7.75% Insiders
28.04% Mutual Funds
19.17% Other Institutional Investors
21.53% Public Companies and Individual Investors